CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
about
Phytochemicals: a multitargeted approach to gynecologic cancer therapy.Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC levelInhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenanceSprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinomaMolecular and genetic properties of tumors associated with local immune cytolytic activity.Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILCK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.Endometrial carcinoma: molecular alterations involved in tumor development and progression.Molecular pathology of endometrial carcinoma.Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line.Luteolin induces apoptosis by activating Fas signaling pathway at the receptor level in laryngeal squamous cell line Hep-2 cells.Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.Inhibition of WNT-CTNNB1 signaling upregulates SQSTM1 and sensitizes glioblastoma cells to autophagy blockers.
P2860
Q33908881-93A416C7-B7E1-4673-A8B2-9CAC03C5072CQ33936620-497644EA-F59C-4EFE-816A-EA472F8D14ADQ33959504-EC7F13ED-8A5F-4B5F-8603-E757B1E027C2Q34805471-3EB8AB5C-BB79-4D2B-8888-CEA0443FA73CQ35051505-2D4CE697-6503-435D-A597-4E3B2E939541Q35783593-C3243B7C-CA69-4076-AC02-3D646DB4EFE8Q35990014-19C54420-489A-44BF-B77B-C596E8186E7AQ36043347-B71A39FB-A9E4-483D-81C3-5C73B51E782FQ36869059-280A534E-7C41-48A3-8B69-EB5F72334043Q37000191-AB59C8A3-FAEC-4B1C-8A0C-AE94FD9306E3Q37073822-13BAD876-0F02-408E-A41D-40BC552B7B6DQ37994980-C9733254-6F32-4166-950C-AD253B14B48AQ38067440-EBD1EB8D-C3BB-44B0-895A-4715BEAA25A6Q38853393-30165B68-F7B3-4A3D-8ECE-BC9A52208CE1Q39029198-9509D792-9903-4C9B-962D-C7169F776258Q39053372-D5079EAA-2FD7-41C6-823F-F715F239BB33Q39165456-7C8FC65E-786F-4B29-80A8-26C77D9DD344Q39184863-69F38F3D-84B4-4504-BB3C-AC72160CAACCQ47219767-6D8721E8-A256-4F7E-B3EA-136BF22E6422
P2860
CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CK2 controls TRAIL and Fas sen ...... n endometrial carcinoma cells.
@en
type
label
CK2 controls TRAIL and Fas sen ...... n endometrial carcinoma cells.
@en
prefLabel
CK2 controls TRAIL and Fas sen ...... n endometrial carcinoma cells.
@en
P2093
P2860
P356
P1433
P1476
CK2 controls TRAIL and Fas sen ...... in endometrial carcinoma cells
@en
P2093
A Yeramian
F J Gonzalez-Tallada
J Pallares
X Matias-Guiu
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210924
P407
P577
2007-11-05T00:00:00Z
P5875
P6179
1049640882